Myriad Genetics has been granted a patent for a method of high-fidelity nucleic acid sequencing. The method involves using sequencing adapters with molecular barcodes to reduce sequencing errors. The adapters are ligated to the nucleic acid molecule before amplification and sequencing, resulting in accurate and reliable sequencing results. This method can be used for various applications, including identifying errors in nucleic acid sequences and determining the number of nucleic acid molecules in a library. GlobalData’s report on Myriad Genetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Myriad Genetics, Personalized medicine biomarkers was a key innovation area identified from patents. Myriad Genetics's grant share as of September 2023 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for high-fidelity nucleic acid sequencing method
A recently granted patent (Publication Number: US11708574B2) describes a method for sequencing a nucleic acid molecule. The method involves mixing a plurality of sequencing adaptors with a duplex nucleic acid molecule and ligating the adaptors to the molecule before amplification. The sequencing adaptors include a first sequence adaptor and a second sequence adaptor, each containing a duplex molecular barcode consisting of a specific number of base positions. The first sequence adaptor has a U-shaped or Y-shaped structure and a predetermined base fraction at certain base positions, while the second sequence adaptor has a U-shaped or Y-shaped structure and a larger duplex molecular barcode with an additional base position. The adaptors also have a constant 3'-overhang with a thymine residue adjacent to the duplex molecular barcode.
After amplification of the duplex nucleic acid molecule, a set of first strand reads is obtained through sequencing. These reads are then used to construct a first strand consensus sequence by comparing and identifying errors in the reads. The method also includes the option of sequencing the second strand of the duplex nucleic acid molecule and constructing a second strand consensus sequence using the set of second strand reads. Errors in both the first and second strand reads can be identified and corrected to generate an error-corrected duplex consensus sequence.
The patent also mentions the use of sample index nucleic acid sequences within the sequencing adaptors, with specific proportions of adenine, cytosine, thymidine, and guanine. Additionally, the method can be applied to cell-free DNA molecules or enriched nucleic acid libraries using capture probes.
Overall, this patent describes a method for sequencing nucleic acid molecules that involves the use of specific sequencing adaptors with duplex molecular barcodes and constant 3'-overhangs. The method allows for the construction of consensus sequences and error correction, potentially improving the accuracy of nucleic acid sequencing.
To know more about GlobalData’s detailed insights on Myriad Genetics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
